Mnemosyne Pharmaceuticals (Providence, RI) a development-stage small molecule company focused on neuropsychiatric disorders such as schizophrenia and Alzheimer’s, closed a $5.4M Series financing Participants include Access BridgeGap Ventures and Slater Technology Fund.

Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.